Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Peter Anderson to Adenine

This is a "connection" page, showing publications Peter Anderson has written about Adenine.

 
Connection Strength
  
 
 
9.892
  
  1. Yager J, Castillo-Mancilla J, Ibrahim ME, Brooks KM, McHugh C, Morrow M, McCallister S, Bushman LR, MaWhinney S, Kiser JJ, Anderson PL. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. J Acquir Immune Defic Syndr. 2020 07 01; 84(3):323-330.
    View in: PubMed
    Score: 0.590
  2. Brooks KM, Ibrahim ME, Castillo-Mancilla JR, MaWhinney S, Alexander K, Tilden S, Kerr BJ, Ellison L, McHugh C, Bushman LR, Kiser JJ, Hosek S, Huhn GD, Anderson PL. Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate. J Antimicrob Chemother. 2019 08 01; 74(8):2352-2359.
    View in: PubMed
    Score: 0.553
  3. Castillo-Mancilla JR, Morrow M, Coyle RP, Coleman SS, Gardner EM, Zheng JH, Ellison L, Bushman LR, Kiser JJ, Mawhinney S, Anderson PL. Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections. Clin Infect Dis. 2019 04 08; 68(8):1335-1342.
    View in: PubMed
    Score: 0.541
  4. Anderson PL, Liu AY, Castillo-Mancilla JR, Gardner EM, Seifert SM, McHugh C, Wagner T, Campbell K, Morrow M, Ibrahim M, Buchbinder S, Bushman LR, Kiser JJ, MaWhinney S. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. Antimicrob Agents Chemother. 2018 01; 62(1).
    View in: PubMed
    Score: 0.495
  5. Zheng JH, Rower C, McAllister K, Castillo-Mancilla J, Klein B, Meditz A, Guida LA, Kiser JJ, Bushman LR, Anderson PL. Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. J Pharm Biomed Anal. 2016 Apr 15; 122:16-20.
    View in: PubMed
    Score: 0.433
  6. Castillo-Mancilla JR, Meditz A, Wilson C, Zheng JH, Palmer BE, Lee EJ, Gardner EM, Seifert S, Kerr B, Bushman LR, MaWhinney S, Anderson PL. Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals. J Acquir Immune Defic Syndr. 2015 Apr 15; 68(5):495-501.
    View in: PubMed
    Score: 0.411
  7. Anderson PL, Glidden DV, Bushman LR, Heneine W, Garc?a-Lerma JG. Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission. J Antimicrob Chemother. 2014 Sep; 69(9):2470-6.
    View in: PubMed
    Score: 0.386
  8. Zheng JH, Guida LA, Rower C, Castillo-Mancilla J, Meditz A, Klein B, Kerr BJ, Langness J, Bushman L, Kiser J, Anderson PL. Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS. J Pharm Biomed Anal. 2014 Jan; 88:144-51.
    View in: PubMed
    Score: 0.367
  9. Castillo-Mancilla JR, Zheng JH, Rower JE, Meditz A, Gardner EM, Predhomme J, Fernandez C, Langness J, Kiser JJ, Bushman LR, Anderson PL. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013 Feb; 29(2):384-90.
    View in: PubMed
    Score: 0.345
  10. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, McMahan V, Bushman LR, Casap?a M, Montoya-Herrera O, Veloso VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kall?s EG, Grant RM. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012 Sep 12; 4(151):151ra125.
    View in: PubMed
    Score: 0.343
  11. Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother. 2011 Feb; 66(2):240-50.
    View in: PubMed
    Score: 0.303
  12. Anderson PL, Kakuda TN. Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. J Antimicrob Chemother. 2006 Jul; 58(1):220-1.
    View in: PubMed
    Score: 0.222
  13. Mainella VA, Branchford B, Nemkov T, Hosford S, Coyle RP, Johnson B, Choi YJ, Williams M, Zheng JH, Bushman L, Kiser JJ, Anderson PL, Brooks KM. Cellular pharmacology of tenofovir alafenamide and emtricitabine in neutrophils and platelets in people with and without HIV. J Antimicrob Chemother. 2025 May 02; 80(5):1224-1232.
    View in: PubMed
    Score: 0.206
  14. McGarrity MW, MacPherson P, Li A, Naccarato M, Anderson P, Tan DHS. Intracellular tenofovir-diphosphate concentrations in HIV pre-exposure prophylaxis users who underwent bariatric surgery. HIV Med. 2025 Apr; 26(4):643-649.
    View in: PubMed
    Score: 0.202
  15. Coyle RP, Morrow M, Mann SC, Mainella V, Ellis SL, Schwab S, Coppinger C, Barker N, Ellison L, Zheng JH, Al Zuabi S, Alpert PE, Carnes TC, Buffkin DE, Chai PR, Bushman LR, Kiser JJ, MaWhinney S, Brooks KM, Anderson PL, Castillo-Mancilla JR. Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons With HIV Receiving Tenofovir Alafenamide and Emtricitabine-Based Antiretroviral Therapy (QUANTI-TAF). Clin Infect Dis. 2024 11 22; 79(5):1233-1241.
    View in: PubMed
    Score: 0.200
  16. Joseph Davey D, Dadan S, Bheemraj K, Waitt C, Khoo S, Myer L, Wiesner L, Else L, Thompson B, Castel S, Wara N, Anderson PL, Orrell C. Evaluation of pharmacokinetics of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil (TDF) in pregnant and postpartum women in South Africa: PrEP-PP PK study. Antiviral Res. 2024 Nov; 231:106014.
    View in: PubMed
    Score: 0.198
  17. Riddler SA, Kelly CW, Hoesley CJ, Ho KS, Piper JM, Edick S, Heard F, Doncel GF, Johnson S, Anderson PL, Brand RM, Kunjara Na Ayudhya RP, Bauermeister JA, Hillier SL, Hendrix CW. A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention. J Infect Dis. 2024 Sep 23; 230(3):696-705.
    View in: PubMed
    Score: 0.198
  18. Patel N, Morris S, Burke L, Chow K, Pacheco D, Anderson P, Stancyzk F, Blumenthal J. No observed bidirectional effect between tenofovir diphosphate concentrations and gender-affirming hormone concentrations among transgender persons switching from tenofovir disoproxil fumarate/emtricitabine to tenofovir alafenamide/emtricitabine for HIV pre-exposure prophylaxis. Br J Clin Pharmacol. 2024 Oct; 90(10):2360-2365.
    View in: PubMed
    Score: 0.192
  19. Lartey M, Ganu VJ, Tachi K, Yang H, Anderson PL, Langaee T, Ojewale O, Boamah I, Obo-Akwa A, Antwi K, Bushman LR, Ellison L, Kwara A. Association of tenofovir diphosphate and lamivudine triphosphate concentrations with HIV and hepatitis B virus viral suppression. AIDS. 2024 03 01; 38(3):351-362.
    View in: PubMed
    Score: 0.186
  20. Beauchamp G, Hosek S, Donnell D, Chan KCG, Anderson PL, Dye BJ, Mgodi N, Bekker LG, Delany-Moretlwe S, Celum C. The Effect of Disclosure of PrEP Use on Adherence Among African Young Women in an Open-Label PrEP Study: Findings from HPTN 082. AIDS Behav. 2024 May; 28(5):1512-1521.
    View in: PubMed
    Score: 0.185
  21. Abuogi LL, Castillo-Mancilla J, Hampanda K, Owuor K, Odwar T, Onono M, Helova A, Turan JM, Anderson PL. Tenofovir Diphosphate in Dried Blood Spots in Pregnant and Postpartum Women With HIV in Kenya: A Novel Approach to Measuring Peripartum Adherence. J Acquir Immune Defic Syndr. 2022 03 01; 89(3):310-317.
    View in: PubMed
    Score: 0.165
  22. Celum C, Hosek S, Tsholwana M, Kassim S, Mukaka S, Dye BJ, Pathak S, Mgodi N, Bekker LG, Donnell DJ, Wilson E, Yuha K, Anderson PL, Agyei Y, Noble H, Rose SM, Baeten JM, Fogel JM, Adeyeye A, Wiesner L, Rooney J, Delany-Moretlwe S. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial. PLoS Med. 2021 06; 18(6):e1003670.
    View in: PubMed
    Score: 0.158
  23. Saderup AM, Morrow M, Libby AM, Coyle RP, Coleman SS, Zheng JH, Ellison L, Bushman LR, Kiser JJ, MaWhinney S, Anderson PL, Castillo-Mancilla JR. Higher medication complexity in persons with HIV is associated with lower tenofovir diphosphate in dried blood spots. Pharmacotherapy. 2021 03; 41(3):291-298.
    View in: PubMed
    Score: 0.153
  24. Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, DeJesus E, Jessen H, Grant RM, Ruane PJ, Wong P, Ebrahimi R, Zhong L, Mathias A, Callebaut C, Collins SE, Das M, McCallister S, Brainard DM, Brinson C, Clarke A, Coll P, Post FA, Hare CB. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020 07 25; 396(10246):239-254.
    View in: PubMed
    Score: 0.148
  25. Pu F, Pandey S, Bushman LR, Anderson PL, Ouyang Z, Cooks RG. Direct quantitation of tenofovir diphosphate in human blood with mass spectrometry for adherence monitoring. Anal Bioanal Chem. 2020 Feb; 412(6):1243-1249.
    View in: PubMed
    Score: 0.142
  26. Brooks KM, Castillo-Mancilla JR, Blum J, Huntley R, MaWhinney S, Alexander K, Kerr BJ, Ellison L, Bushman LR, MacBrayne CE, Anderson PL, Kiser JJ. Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir. J Antimicrob Chemother. 2019 08 01; 74(8):2360-2364.
    View in: PubMed
    Score: 0.138
  27. Morrow M, MaWhinney S, Coyle RP, Coleman SS, Gardner EM, Zheng JH, Ellison L, Bushman LR, Kiser JJ, Anderson PL, Castillo-Mancilla JR. Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV. J Infect Dis. 2019 07 19; 220(4):635-642.
    View in: PubMed
    Score: 0.138
  28. Yager JL, Coyle RP, Coleman SS, Ellison L, Zheng JH, Bushman L, Gardner EM, Morrow M, MaWhinney S, Anderson PL, Justice Kiser J, Castillo-Mancilla JR. Moderately High Tenofovir Diphosphate in Dried Blood Spots Indicates Drug Resistance in Viremic Persons Living with HIV. J Int Assoc Provid AIDS Care. 2019 Jan-Dec; 18:2325958219888457.
    View in: PubMed
    Score: 0.133
  29. Pyra M, Anderson PL, Hendrix CW, Heffron R, Mugwanya K, Haberer JE, Thomas KK, Celum C, Donnell D, Marzinke MA, Bukusi EA, Mugo NR, Asiimwe S, Katabira E, Baeten JM. Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis. AIDS. 2018 08 24; 32(13):1891-1898.
    View in: PubMed
    Score: 0.130
  30. Chua CYX, Jain P, Ballerini A, Bruno G, Hood RL, Gupte M, Gao S, Di Trani N, Susnjar A, Shelton K, Bushman LR, Folci M, Filgueira CS, Marzinke MA, Anderson PL, Hu M, Nehete P, Arduino RC, Sastry JK, Grattoni A. Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis. J Control Release. 2018 09 28; 286:315-325.
    View in: PubMed
    Score: 0.129
  31. Moore DJ, Jain S, Dub? MP, Daar ES, Sun X, Young J, Corado K, Ellorin E, Milam J, Collins D, Blumenthal J, Best BM, Anderson P, Haubrich R, Morris SR. Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study. Clin Infect Dis. 2018 05 02; 66(10):1566-1572.
    View in: PubMed
    Score: 0.127
  32. Hoornenborg E, Prins M, Achterbergh RCA, Woittiez LR, Cornelissen M, Jurriaans S, Kootstra NA, Anderson PL, Reiss P, de Vries HJC, Prins JM, de Bree GJ. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report. Lancet HIV. 2017 11; 4(11):e522-e528.
    View in: PubMed
    Score: 0.121
  33. Castillo-Mancilla JR, Searls K, Caraway P, Zheng JH, Gardner EM, Predhomme J, Bushman LR, Anderson PL, Meditz AL. Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women. AIDS Res Hum Retroviruses. 2015 Apr; 31(4):428-32.
    View in: PubMed
    Score: 0.100
  34. Liu AY, Yang Q, Huang Y, Bacchetti P, Anderson PL, Jin C, Goggin K, Stojanovski K, Grant R, Buchbinder SP, Greenblatt RM, Gandhi M. Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS One. 2014; 9(1):e83736.
    View in: PubMed
    Score: 0.094
  35. Bushman LR, Kiser JJ, Rower JE, Klein B, Zheng JH, Ray ML, Anderson PL. Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J Pharm Biomed Anal. 2011 Sep 10; 56(2):390-401.
    View in: PubMed
    Score: 0.079
  36. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casap?a M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fern?ndez T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kall?s EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010 Dec 30; 363(27):2587-99.
    View in: PubMed
    Score: 0.076
  37. Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr. 2008 Mar 01; 47(3):298-303.
    View in: PubMed
    Score: 0.063
  38. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, Delahunty T, Bushman LR, Fletcher CV. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008 Feb; 83(2):265-72.
    View in: PubMed
    Score: 0.060
  39. King T, Bushman L, Kiser J, Anderson PL, Ray M, Delahunty T, Fletcher CV. Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Nov 07; 843(2):147-56.
    View in: PubMed
    Score: 0.056
  40. Hiransuthikul A, Thammajaruk N, Kerr S, Janamnuaysook R, Nonenoy S, Hongchookiat P, Trichavaroj R, Tawon Y, Boonruang J, Teeratakulpisarn N, Cressey TR, Anderson PL, Phanuphak N. No significant drug-drug interaction between oral TAF-based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT-3 study. J Int AIDS Soc. 2025 May; 28(5):e26502.
    View in: PubMed
    Score: 0.052
  41. Hiransuthikul A, Thammajaruk N, Kerr S, Janamnuaysook R, Nonenoy S, Hongchookiat P, Trichavaroj R, Tawon Y, Boonruang J, Teeratakulpisarn N, Cressey TR, Anderson PL, Phanuphak N. Exploring potential drug-drug interactions between masculinizing hormone therapy and oral pre-exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open-label pharmacokinetic study in Thailand. J Int AIDS Soc. 2025 Apr; 28(4):e26445.
    View in: PubMed
    Score: 0.051
  42. Kakuda TN, Anderson PL, Becker SL. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. AIDS. 2004 Dec 03; 18(18):2442-4.
    View in: PubMed
    Score: 0.050
  43. Gichane MW, Velloza J, Hosek S, Beauchamp G, Anderson P, Delany-Moretlwe S, Celum C. Hoping to Adhere? Examining the Relationship Between Hope and Pre-exposure Prophylaxis Willingness, Adherence, and Persistence Among Young Women in South Africa and Zimbabwe (HPTN 082). AIDS Behav. 2025 Feb; 29(2):527-534.
    View in: PubMed
    Score: 0.050
  44. Wu L, Kinuthia J, Anderson PL, Baeten JM, Dettinger JC, Gandhi M, Gomez L, John-Stewart G, Marwa MM, Ngumbau N, Otieno F, Omondi P, Odhiambo B, Watoyi S, Pintye J. Drug Concentrations in Hair and Dried Blood Spots as Preexposure Prophylaxis Adherence Metrics During Pregnancy and Postpartum. J Infect Dis. 2024 Sep 23; 230(3):689-695.
    View in: PubMed
    Score: 0.049
  45. Bae J, Tantawy M, Gong Y, Langaee T, Lartey M, Ganu V, Tachi K, Ojewale O, Obo-Akwa A, Boamah I, Bushman LR, Ellison L, Yang H, Anderson PL, Kwara A. Pharmacogenetic determinants of tenofovir diphosphate and lamivudine triphosphate concentrations in people with HIV/HBV coinfection. Antimicrob Agents Chemother. 2024 09 04; 68(9):e0054924.
    View in: PubMed
    Score: 0.049
  46. Wijstma ES, Jongen VW, Boyd A, van den Elshout MAM, de Vries HJC, Davidovich U, Anderson PL, Prins M, Hoornenborg E, Schim van der Loeff MF. Concordance between daily diary reported pre-exposure prophylaxis intake and intraerythrocytic tenofovir diphosphate in the Amsterdam Pre-exposure Prophylaxis demonstration project. AIDS. 2024 07 01; 38(8):1248-1256.
    View in: PubMed
    Score: 0.048
  47. Pons-Faudoa FP, Di Trani N, Capuani S, Hernandez N, Wood AM, Nehete B, Niles J, Shelton KA, Kezar S, Bushman LR, Chua CYX, Ittmann MM, Anderson PL, Nehete PN, Arduino RC, Nichols JE, Grattoni A. Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates. J Control Release. 2023 06; 358:116-127.
    View in: PubMed
    Score: 0.045
  48. Velloza J, Donnell D, Hosek S, Anderson PL, Chirenje ZM, Mgodi N, Bekker LG, Marzinke MA, Delany-Moretlwe S, Celum C. Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial. Lancet HIV. 2022 10; 9(10):e680-e689.
    View in: PubMed
    Score: 0.043
  49. Coyle RP, Morrow M, MaWhinney S, Coleman SS, Zheng JH, Ellison L, Bushman LR, Kiser JJ, Anderson PL, Castillo-Mancilla JR. Cumulative tenofovir diphosphate exposure in persons with HIV taking single- vs. multiple-tablet regimens. Pharmacotherapy. 2022 08; 42(8):641-650.
    View in: PubMed
    Score: 0.042
  50. Jennings L, Robbins RN, Nguyen N, Ferraris C, Leu CS, Dolezal C, Hsiao NY, Mgbako O, Joska J, Castillo-Mancilla JR, Myer L, Anderson PL, Remien RH, Orrell C. Tenofovir diphosphate in dried blood spots predicts future viremia in persons with HIV taking antiretroviral therapy in South Africa. AIDS. 2022 06 01; 36(7):933-940.
    View in: PubMed
    Score: 0.041
  51. Castillo-Mancilla JR, Edwards JA, Brijkumar J, Moosa MY, Zhao Y, Ofotokun I, Johnson BA, Lee MH, Pillay S, Pillay M, Moodley P, Kuritzkes DR, Sunpath H, Bushman LR, Ellison L, Anderson PL, Marconi VC. Tenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to first-line therapy in South Africa: a case-control cohort study. J Int AIDS Soc. 2021 12; 24(12):e25849.
    View in: PubMed
    Score: 0.041
  52. Grant RM, Pellegrini M, Defechereux PA, Anderson PL, Yu M, Glidden DV, O'Neal J, Yager J, Bhasin S, Sevelius J, Deutsch MB. Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study. Clin Infect Dis. 2021 10 05; 73(7):e2117-e2123.
    View in: PubMed
    Score: 0.040
  53. Stranix-Chibanda L, Anderson PL, Kacanek D, Hosek S, Huang S, Nematadzira TG, Taulo F, Korutaro V, Nakabiito C, Masenya M, Lypen K, Brown E, Ibrahim ME, Yager J, Wiesner L, Johnston B, Amico KR, Rooney JF, Chakhtoura N, Spiegel HML, Chi BH. Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa. Clin Infect Dis. 2021 10 05; 73(7):e1893-e1900.
    View in: PubMed
    Score: 0.040
  54. Goldwirt L, Bauer R, Liegeon G, Charreau I, Delaugerre C, Cotte L, Pialou G, Cua E, Laghzal A, Buschman L, Anderson PL, Mourah S, Meyer L, Molina JM. Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial. J Antimicrob Chemother. 2021 09 15; 76(10):2675-2680.
    View in: PubMed
    Score: 0.040
  55. Peterson S, Ibrahim M, Anderson PL, Moore CM, MaWhinney S. A comparison of covariate selection techniques applied to pre-exposure prophylaxis (PrEP) drug concentration data in men and transgender women at risk for HIV. J Pharmacokinet Pharmacodyn. 2021 10; 48(5):655-669.
    View in: PubMed
    Score: 0.039
  56. Ellsworth GB, Burke LA, Wells MT, Mishra S, Caffrey M, Liddle D, Madhava M, O'Neal C, Anderson PL, Bushman L, Ellison L, Stein J, Gulick RM. Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment. J Acquir Immune Defic Syndr. 2021 01 01; 86(1):73-80.
    View in: PubMed
    Score: 0.038
  57. Brooks KM, Castillo-Mancilla JR, Morrow M, MaWhinney S, Blum J, Wyles DL, Rowan SE, Ibrahim ME, Zheng JH, Johnson B, Gomez J, Choi YJ, Cendali F, Haas H, Roon L, Bushman LR, Anderson PL, Kiser JJ. Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. J Antimicrob Chemother. 2020 11 01; 75(11):3303-3310.
    View in: PubMed
    Score: 0.038
  58. Spinelli MA, Haberer JE, Chai PR, Castillo-Mancilla J, Anderson PL, Gandhi M. Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions. Curr HIV/AIDS Rep. 2020 08; 17(4):301-314.
    View in: PubMed
    Score: 0.037
  59. Sizovs A, Pons-Faudoa FP, Malgir G, Shelton KA, Bushman LR, Chua CYX, Anderson PL, Nehete PN, Sastry KJ, Grattoni A. Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications. Int J Pharm. 2020 Sep 25; 587:119623.
    View in: PubMed
    Score: 0.037
  60. Coyle RP, Morrow M, Coleman SS, Gardner EM, Zheng JH, Ellison L, Bushman LR, Kiser JJ, MaWhinney S, Anderson PL, Castillo-Mancilla JR. Factors associated with tenofovir diphosphate concentrations in dried blood spots in persons living with HIV. J Antimicrob Chemother. 2020 06 01; 75(6):1591-1598.
    View in: PubMed
    Score: 0.037
  61. Coyle RP, Schneck CD, Morrow M, Coleman SS, Gardner EM, Zheng JH, Ellison L, Bushman LR, Kiser JJ, Mawhinney S, Anderson PL, Castillo-Mancilla JR. Engagement in Mental Health Care is Associated with Higher Cumulative Drug Exposure and Adherence to Antiretroviral Therapy. AIDS Behav. 2019 Dec; 23(12):3493-3502.
    View in: PubMed
    Score: 0.035
  62. Hoenigl M, Hassan A, Moore DJ, Anderson PL, Corado K, Dub? MP, Ellorin EE, Blumenthal J, Morris SR. Predictors of Long-Term HIV Pre-exposure Prophylaxis Adherence After Study Participation in Men Who Have Sex With Men. J Acquir Immune Defic Syndr. 2019 06 01; 81(2):166-174.
    View in: PubMed
    Score: 0.034
  63. Spinelli MA, Glidden DV, Anderson PL, Gandhi M, Cohen S, Vittinghoff E, Coleman ME, Scott H, Bacon O, Elion R, Kolber MA, Buchbinder SP, Liu AY. Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing. J Acquir Immune Defic Syndr. 2019 06 01; 81(2):158-162.
    View in: PubMed
    Score: 0.034
  64. Goodman-Meza D, Beymer MR, Kofron RM, Amico KR, Psaros C, Bushman LR, Anderson PL, Bolan R, Jordan WC, Rooney JF, Wohl AR, Landovitz RJ. Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles. AIDS Care. 2019 10; 31(10):1228-1233.
    View in: PubMed
    Score: 0.034
  65. MacBrayne CE, Marks KM, Fierer DS, Naggie S, Chung RT, Hughes MD, Kim AY, Peters MG, Brainard DM, Seifert SM, Castillo-Mancilla JR, Bushman LR, Anderson PL, Kiser JJ. Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. J Antimicrob Chemother. 2018 08 01; 73(8):2112-2119.
    View in: PubMed
    Score: 0.032
  66. Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, Chege W, Postle BS, Matheson T, Amico KR, Liegler T, Rawlings MK, Trainor N, Blue RW, Estrada Y, Coleman ME, Cardenas G, Feaster DJ, Grant R, Philip SS, Elion R, Buchbinder S, Kolber MA. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. JAMA Intern Med. 2016 Jan; 176(1):75-84.
    View in: PubMed
    Score: 0.027
  67. Liegler T, Abdel-Mohsen M, Bentley LG, Atchison R, Schmidt T, Javier J, Mehrotra M, Eden C, Glidden DV, McMahan V, Anderson PL, Li P, Wong JK, Buchbinder S, Guanira JV, Grant RM. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. J Infect Dis. 2014 Oct 15; 210(8):1217-27.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)